| Autor: |
Bostanci, Birol, Eren, Tulay, Karacin, Cengiz, Ucar, Gokhan, Ergun, Yakup, YAZICI, OZAN, Imamoglu, Goksen Inanc, Ozdemir, NURİYE |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Popis: |
Our study aimed to evaluate the efficacy and demonstrate the real-life outcomes of the combination of modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as perioperative chemotherapy in patients with locally advanced gastric cancer. The study included 151 patients diagnosed with locally advanced gastric cancer. Modified Docetaxel, Cisplatin, and Fluorouracil was given to patients every 21 days with the following dosages per medication: Docetaxel: 60 mg/m(2), Day 1; Cisplatin: 60 mg/m(2), Day 1; 5-Fluorouracil: 600 mg/ m 2 X 5 days. After perioperative chemotherapy patients considered resectable underwent subtotal/total gastrectomy. One hundred and thirty-four (88.7%) of the 151 patients receiving perioperative treatment were operated on. Complete resection was achieved in 123 (81.4%) of the 151 patients. The median disease-free survival (DFS) was 16 months (95% CI 22.5-31.5) and 5-year DFS was 25%. Median overall survival (OS) was 29 (95% CI, 21.9-36.0) months and 5-year OS was 29%. The presence of lymphovascular invasion and postoperative metastatic lymph node rate being >= 0.15 in the multivariate Cox regression analysis were determined as independent prognostic factors in terms of both DFS and OS. Our study has provided significant data in terms of sharing long-term real-life outcomes of perioperative mDCF. With mDCF combination in locally advanced gastric cancer, high RO resection rates were obtained. Furthermore, our study put forward that MLR and LVI are two parameters that could be used in determining the prognosis of patients receiving perioperative mDCF. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
